Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7848795 | 1.00 | CYP2C9 (0.37) | CYP2C9TSHRCYP2C19TDP1MAPK1 | |
| SCHEMBL551635 | 1.00 | CYP2C9 (0.37) | CYP2C9TSHRCYP2C19TDP1MAPK1 | |
| SCHEMBL550510 | 0.96 | CYP2C9 (0.39) | CYP2C9TSHRCYP2C19TDP1MAPK1 | |
| SCHEMBL21965258 | 0.96 | MAPK1 (0.38) | CYP2C9TSHRCYP2C19TDP1MAPK1 | |
| Hydrochloric Acid SCHEMBL1819609 | 0.92 | CYP2C9 (0.37) | CYP2C9TSHRCYP2C19TDP1MAPK1 | |
| SCHEMBL16878579 | 0.92 | MAPK1 (0.36) | CYP2C9TSHRCYP2C19TDP1MAPK1 | |
| SCHEMBL550429 | 0.92 | — | — | |
| SCHEMBL14545648 | 0.92 | — | — | |
| SCHEMBL9464271 | 0.92 | ALDH1A1 (0.36) | CYP2C9TSHRCYP2C19TDP1MAPK1 | |
| SCHEMBL2290579 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2880033-B1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10584110-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2020-03-10 | — | — | US | disclosed |
| EP-3564240-A1 | PIPERIDINE INTERMEDIATES | Purdue Pharma L.P. (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10118927-B2 | Substituted piperidin-4-amino-type compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2018-11-06 | — | — | US | disclosed |
| US-20180208575-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2018-07-26 | — | — | US | disclosed |
| US-9951038-B2 | Quinazolin-4(3H)-one-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9878991-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2018-01-30 | — | — | US | disclosed |
| EP-2709609-B1 | HETEROCYCLIC COMPOUNDS | SHIONOGI & CO (JP) | 2017-10-04 | — | — | EP | disclosed |
| US-9598411-B2 | Substituted benzimidazole-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598447-B2 | Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2433937-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| US-8110602-B2 | Compounds comprising heterocyclic-substituted piperidine for treating pain | PURDUE PHARMA L.P. (US) | 2012-02-07 | — | — | US | disclosed |
| EP-2397477-A1 | Heterocyclic-substituted piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2280008-A2 | Heterocyclic-substituted piperidines as ORL-1 ligands | Purdue Pharma L.P. (US) | 2011-02-02 | — | — | EP | disclosed |
| EP-2076506-B1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINES AS ORL-1 LIGANDS | PURDUE PHARMA LP (US) | 2010-09-22 | — | — | EP | disclosed |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100022519-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2010-01-28 | — | — | US | disclosed |
| US-20090176796-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L. P. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090170868-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L. P. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170867-A1 | TRPV1 ANTAGONISTS INCLUDING SULFONAMIDE SUBSTITUENT AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | P2RX4, P2RX5, P2RX3 | CYP2C9 932/4885TSHR 4787/4885CYP2C19 909/4885 |
| US-20100022519-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | TRPV1, P2RX4, TRPA1 | CYP2C9 421/4885TSHR 4678/4885CYP2C19 285/4885 |
| US-20180208575-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV5 | CYP2C9 1165/4885TSHR 3640/4885CYP2C19 548/4885 |
| US-10118927-B2 | Substituted piperidin-4-amino-type compounds and uses thereof | OPRD1, OPRL1, P2RX4 | CYP2C9 679/4885TSHR 4445/4885CYP2C19 540/4885 |
| US-20090176796-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV2 | CYP2C9 1406/4885TSHR 3037/4885CYP2C19 935/4885 |
| US-20090170868-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV5 | CYP2C9 1165/4885TSHR 3640/4885CYP2C19 548/4885 |
| US-10584110-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | TRPV1, TRPA1, TRPV5 | CYP2C9 1165/4885TSHR 3640/4885CYP2C19 548/4885 |
| US-20090170867-A1 | TRPV1 ANTAGONISTS INCLUDING SULFONAMIDE SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV5 | CYP2C9 1414/4885TSHR 3310/4885CYP2C19 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.